Registry for GammaPod and Quality of Life in Breast Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to collect data on patient outcomes, adverse events, and dosimetric characteristics associated with the GammaPod, a device used for delivering a single-fraction boost in breast cancer treatment. It focuses on women who have undergone breast-conserving therapy after surgical lumpectomy for early-stage breast cancer. The study will evaluate the feasibility and effectiveness of this treatment approach while also assessing the quality of life of participants. By gathering this information, the study seeks to improve treatment protocols and patient care in breast cancer management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* The patient must sign consent for study participation.
* The patient must be female and have a diagnosis of an invasive or non-invasive breast cancer that was treated surgically by a partial mastectomy.
* The patient must be deemed an appropriate candidate for breast conserving therapy (i.e. not pregnant, never had radiation to the treated breast, breast size would allow adequate cosmesis after volume loss from partial mastectomy).
* Patients with involved lymph nodes are candidates for the study.
* Surgical margins are negative for invasive (no tumor on ink) or non-invasive breast cancer (2 mm negative margin).
* The greatest dimension of the tumor is less than 4cm before surgery.
* Multifocal disease is allowed if it was removed by a single lumpectomy resection and the patient remained a candidate for breast conservation.
* Age 18 years and older.
* Women of childbearing potential (pre-menopausal defined as having a menstrual period within the past 1 year) must have a negative serum pregnancy test or complete a pregnancy waiver form per institutional policy.
* The surgical cavity is clearly visible on CT images. Of note, clips are not required but recommended.
* The patient must weigh less than 150Kg (330lb), which is the limit of the imaging couch.
* The patient must be less than 6'6" in height.
* The patient must feel comfortable in the prone position.
* Diagnosis of prior contralateral breast cancer is allowed.
* Diagnosis of synchronous bilateral cancers is allowed. In this case if bilateral boosts are required, a patient would not have both treatments on the same day.
* Oncoplastic reduction surgery is allowed if the lumpectomy cavity can be clearly visualized.

Exclusion Criteria:

* Patients with proven multi-centric carcinoma (tumors in different quadrants of the breast or tumor separated by at least 4 cm).
* Prior radiation therapy to that breast or that hemi thorax.
* Unable to fit into the immobilization breast cup with an adequate seal.
* Male gender.
* Patient cannot comfortably be set up in the prone position (i.e. physical disability)
* Unable to fit into the breast immobilization device due to breast size or other anatomical reason.
* Mastectomy is the surgery performed.
* Patient has received prior radiotherapy to the involved breast.
* Tumor bed is less than 3 mm from the skin surface.
* Greater than 50% of the target volume is above the upper border of the table.
* Patients with skin involvement, regardless of tumor size.
* Patients with connective tissue disorders specifically systemic lupus erythematosis, scleroderma, or dermatomyositis.
* Patients with psychiatric or addictive disorders that would preclude obtaining informed consent.
* Patients who are pregnant or lactating due to potential exposure of the fetus to RT and unknown effects of RT to lactating females.
* Patients with breast implants/tissue expanders or flap reconstruction.

Where it's running

• Upper Chesapeake Health
  Bel Air, Maryland, United States Recruiting
• Central Maryland Oncology Center
  Columbia, Maryland, United States Recruiting
• Baltimore Washington Medical Center
  Glen Burnie, Maryland, United States Recruiting
• UTSouthwestern
  Dallas, Texas, United States Recruiting

Study contacts

• Principal investigator: Elizabeth M. Nichols, M.D. — University of Maryland
• Study coordinator: Elizabeth M. Nichols, M.D.
• Email: enichols1@umm.edu
• Phone: 410-328-2324

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oncoliq blood test for early detection of breast cancer

  This project will test whether a blood-based miRNA panel (the Oncoliq Test) can detect early breast cancer in adults 40–70 by comparing newly diagnosed, untreated patients with cancer-free controls.

  Recruiting Oncoliq US Inc · Buenos Aires, Buenos Aires · NCT07331506

• Different skin care approaches to prevent skin reactions after mastectomy radiation

  This study tests three standard skin care methods to see which best prevents radiation dermatitis in people who had a mastectomy and are receiving post-mastectomy radiation therapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07918989

• Negative pressure wound therapy after mastectomy

  This study tests whether a negative pressure dressing after mastectomy reduces fluid build‑up and common wound complications in women with breast cancer.

  Recruiting Dalarna County Council, Sweden · Falun · NCT07607366

• ATUSA 3D automated breast ultrasound for suspicious breast lesions

  This study will test whether the ATUSA 3D automated breast ultrasound system can produce high-quality images that match biopsy results in women with BI-RADS 4 or 5 breast findings.

  Recruiting at 2 sites iSono Health, Inc. · Sacramento, California and 1 other locations · NCT07505797

• Support tool for women with HR+ breast cancer on long-term endocrine therapy

  This study tests a SHIELD web- and app-based portal to help women with hormone receptor–positive breast cancer manage symptoms while on long-term endocrine treatment.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07482384

• Conformal ablative radiotherapy for older women with localized ER-positive, HER2-negative breast cancer choosing non-surgical care

  This study will test whether five focused SABR treatments can control ER-positive, HER2-negative breast tumors up to 5 cm in women aged 65 and older who are opting for non-surgical management.

  Recruiting University of Kansas Medical Center · Kansas City, Kansas and 1 other locations · NCT07242118

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.